Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA 10ml semaglutide vial is not a licensed UK weight-loss product. In the UK, semaglutide for weight management comes as Wegovy, a pre-filled injection pen, not a multi-dose vial measured in millilitres. If you've seen the term online, you're almost certainly looking at compounded or unregulated preparations that sit outside the UK's licensed supply chain — and that distinction matters for your safety. These are prescription-only medicines, and a prescriber must assess your full clinical picture before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've been reading about semaglutide's results, you search online, and you land on a product described as a 10ml semaglutide vial, sometimes labelled with a concentration like 5mg/ml or 10mg/ml. It looks clinical. It has a branded-sounding name. The price is well below anything you've seen from a UK pharmacy. You're wondering whether it's the same thing your friend was prescribed.
It isn't. The licensed UK product, Wegovy, is manufactured by Novo Nordisk as a single-use pre-filled pen. Each pen delivers one pre-set weekly dose. The doses progress from 0.25mg through 0.5mg, 1.0mg, 1.7mg, and up to 2.4mg, and from January 2026, a 7.2mg maintenance dose was also approved by the MHRA. None of those presentations involves a vial. None is measured in millilitres in the way a compounded liquid is. The 10ml format you've encountered has no UK marketing authorisation for weight management. What that means in practice: no independent safety review, no verified concentration, no regulated manufacturing standards applied to the batch you'd be injecting.
The NHS medicines page for semaglutide describes the licensed product and its approved uses, it makes no mention of vials or liquid preparations for weight loss, because none exist in the UK licensing framework. If a seller is offering semaglutide this way, that is itself a signal worth taking seriously before you go any further. You can read more about the broader semaglutide landscape on our semaglutide information page.
Multi-dose vials of semaglutide sold online typically originate from compounding operations outside the UK's regulated supply chain, or from countries with different (or no) regulatory oversight. The risks aren't hypothetical. The MHRA has warned publicly and repeatedly about unlicensed injectable weight-loss products circulating online, including fake pens containing insulin rather than the medicine described on the label, leading to hospitalisations. Enforcement operations through 2025 seized roughly 20 million doses of illegally traded weight-loss medicines, worth around £45 million, and uncovered the first UK site manufacturing counterfeit tirzepatide pens.
For a vial preparation specifically, there are additional practical concerns. Dosing accuracy depends entirely on the person drawing up and injecting the medicine themselves, with no pre-set mechanism. An error in dilution, a contaminated vial, or an incorrectly drawn volume can mean getting far more or far less semaglutide than intended. The MHRA's Yellow Card scheme exists so that patients and clinicians can report suspected adverse reactions and suspect sellers, and reports of unlicensed products are exactly the kind of intelligence it is designed to collect.
The short version: a low price on a 10ml vial is not a bargain. It reflects the absence of the regulatory framework that makes the licensed product what it is. You can also find a fuller overview of what to watch for when comparing providers on our Wegovy price comparison page.
Wegovy is licensed for adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses your full medical history, current medicines, and any contraindications before any treatment is issued. That assessment is not a formality, it's the part that makes the treatment safe for you specifically.
The clinical trial evidence behind the licensed product is substantial. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, alongside lifestyle changes. That evidence base applies to the Wegovy pen manufactured under Novo Nordisk's quality standards, it says nothing about a compounded vial of unknown provenance.
Pregnancy, breastfeeding, and trying to conceive are situations where semaglutide is not recommended. The medicine is not licensed for under-18s. Anyone with a history of medullary thyroid carcinoma or MEN2 syndrome should discuss this with a prescriber before any GLP-1 treatment is considered. Worth checking whether Wegovy fits your situation before anything else, our Wegovy treatment page walks through the details, and there's a wider look at weight-loss treatment options if you're still deciding.
The 10ml vial question often comes alongside searches for semaglutide drops or oral liquid preparations, formats that, again, have no UK marketing authorisation for weight management. There is a licensed oral semaglutide tablet for weight loss in the UK, Wegovy tablets, approved by the MHRA in June 2026. That product is a specifically formulated tablet taken once daily, not a liquid or drop. It exists because oral bioavailability of semaglutide is genuinely difficult to achieve, the Wegovy tablet uses a co-formulation with an absorption enhancer to make it work. A generic liquid semaglutide dissolved in a vial does not replicate that mechanism. If you're curious about the tablet format, our page on semaglutide drops and non-injection formats covers what's licensed and what isn't, and if you've also come across listings for a 20ml semaglutide vial, that page explains why that format raises the same concerns. For questions about how the doses and presentations compare, including what distinguishes products like semaglutide 10 from the licensed pen, our FAQs are a good place to start.
If you'd like to explore whether licensed semaglutide treatment is right for you, a consultation with our prescribers is the right next step. Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber (a real clinician, not automated software) and there's no charge for the consultation itself. Start your free consultation when you're ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.